View Post

FDA Okays New CAR T Therapy, First for Mantle Cell Lymphoma

In Clinical Studies News by Barbara Jacoby

By: Nick Mulcahy From: The US Food and Drug Administration (FDA) today granted accelerated approval to brexucabtagene autoleucel (Tecartus, Kite Pharma), the first approved chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). The new agent is the second approved CAR T cell product developed by Kite and follows …